[go: up one dir, main page]

WO2018121702A1 - Composition pharmaceutique d'analogue du glp-1 et son procédé de préparation - Google Patents

Composition pharmaceutique d'analogue du glp-1 et son procédé de préparation Download PDF

Info

Publication number
WO2018121702A1
WO2018121702A1 PCT/CN2017/119613 CN2017119613W WO2018121702A1 WO 2018121702 A1 WO2018121702 A1 WO 2018121702A1 CN 2017119613 W CN2017119613 W CN 2017119613W WO 2018121702 A1 WO2018121702 A1 WO 2018121702A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
weight
composition according
glp
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/119613
Other languages
English (en)
Chinese (zh)
Inventor
丁欢
张新华
张婷婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201780020541.2A priority Critical patent/CN108883073B/zh
Publication of WO2018121702A1 publication Critical patent/WO2018121702A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the present invention belongs to the field of pharmaceutical preparations, and in particular to a pharmaceutical composition comprising a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof.
  • Type 2 diabetes has become a serious global health problem, with a rapid increase in prevalence and 80% of patients from low- and middle-income countries.
  • IDF World Diabetes Federation
  • type II diabetes is the main cause, accounting for more than 90.0%, and most patients have poor control. Therefore, the treatment of diabetes still faces enormous challenges.
  • Changes in the intestinal environment, especially the changes in intestinal hormone levels and effects in the pathogenesis of diabetes, are receiving increasing attention from experts.
  • the change of incretin level and function during the onset of type II diabetes has become a hot topic in the current treatment of diabetes. Therefore, incretin-based treatment has become one of the hotspots in the field of diabetes research in recent years. It is different from the unique mechanism and benefits of traditional hypoglycemic drugs, opening up new ways for the treatment of diabetes.
  • Incretin is mainly composed of GLP-1 (insulinotropic peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), and current incretin-based treatment is mainly divided into two major categories, DPP-4 inhibitors (such as sitagliptin) and GLP-1 receptor agonists (such as exenatide and liraglutide), while exenatide has more effective hypoglycemic effect than liraglutide and sitagliptin It is more obvious to improve the characteristics of ⁇ -cell function.
  • DPP-4 inhibitors Such as sitagliptin
  • GLP-1 receptor agonists such as exenatide and liraglutide
  • exenatide has more effective hypoglycemic effect than liraglutide and sitagliptin It is more obvious to improve the characteristics of ⁇ -cell function.
  • GLP-1 is a gut peptide hormone secreted mainly by the terminal ileum, colon and rectal mucosal L cells, which is also compatible with the existing site of absorption promotion technology.
  • GLP-1 The half-life of natural GLP-1 is very short, only 1 to 2 min. After release, it is rapidly decomposed by dipeptidyl peptidase-4 (DPP-4) and loses its insulin-promoting activity, which cannot reach the therapeutic concentration level of type 2 diabetes.
  • DPP-4 dipeptidyl peptidase-4
  • plasma levels and potency can be increased in two ways: first, structural modification of GLP-1 makes it less susceptible to rapid degradation by DPP-4; second, inhibition of DPP-4 activity, thereby Delay the degradation of endogenous GLP-1.
  • DPP-4 inhibitor the other is GLP-1 receptor agonist. Both types of drugs have been listed in China, and some clinical research has been carried out.
  • CN101987868B discloses a short-acting GLP-1 analogue which is a synthetic GLP-1 derivative containing a palmitic acid structure, the main peptide chain consisting of 40 amino acids. It has high development value, and has a structure of HOOC(CH2)14-CO-lipophilic substituent and the ⁇ -amino group or ⁇ -amino group of the C-terminal Lys of the following amino acid sequence is linked by an amide bond.
  • WO2003072195 discloses an oral formulation comprising a GLP-1 analogue and a specific delivery agent, wherein the delivery agent increases the dissolution and bioavailability of the active ingredient in the pharmaceutical composition.
  • CN102123697A discloses a pharmaceutical composition comprising a protein, a protease inhibitor and an absorption enhancer, wherein by adding an absorption enhancer N-(8-(2-hydroxybenzoyl)amino)octanoate (SNAC) or N- (8-(2-Hydroxybenzoyl)amino) sodium silicate (SNAD) or a combination to enhance protein absorption through the intestinal mucosal barrier; meanwhile, Steinert et al.
  • N-(8-(2-hydroxybenzoyl)amino)octanoate (SNAC) or N- (8-(2-Hydroxybenzoyl)amino) sodium silicate (SNAD) or a combination to enhance protein absorption through the intestinal mucosal barrier; meanwhile, Steinert et al.
  • compositions comprising a GLP-1 analog and N-(8-(2-hydroxybenzoyl)amino)octanoic acid or a sodium salt thereof, respectively, to address the bioavailability of the GLP-1 analog in the composition.
  • CN104487056A discloses a solid composition for protecting a salt of the GLP-1 analogue semaglutide and the delivery agent N-(8-(2-hydroxybenzoyl)amino)octanoic acid (NAC), which composition needs to have a longer Disintegration time, in order to obtain better dissolution and oral bioavailability.
  • NAC N-(8-(2-hydroxybenzoyl)amino)octanoic acid
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a salt of an active ingredient GLP-1 receptor agonist and N-(8-(2-hydroxybenzoyl)amino)octanoic acid (NAC), lactose, which has a dissolution composition Rapid and complete performance, and the preparation process of the pharmaceutical composition is simple, suitable for large-scale production; and the pharmaceutical composition has a disintegration time of 2 to 10 minutes at a total weight of 125 to 250 mg, preferably the disintegration time.
  • the embodiment may be 4, 4.2, 4.5, 4.8, 5, 5.3, 5.5, 5.7, 6.0, 6.5, 7.0, 8.0 minutes.
  • the GLP-1 receptor agonist of the present invention is a GLP-1 analog, optionally comprising a substituent.
  • a GLP-1 analogue of the invention refers to a modified peptide wherein at least one amino acid residue of the peptide is substituted with another amino acid residue, and/or at least one of the amino acid residues is deleted from the peptide, and/or wherein At least one amino acid residue is added to the peptide, and/or wherein at least one amino acid residue of the peptide is modified. This addition or deletion of amino acid residues can be carried out at the N-terminus and/or C-terminus of the peptide.
  • the GLP-1 receptor agonist comprises a substituent covalently linked to a peptide.
  • substituents of the present invention comprise a fatty acid or a fatty diacid, and in some embodiments, the substituent comprises a C16, C18 or C20 fatty acid or a fatty diacid. In a preferred embodiment, the substituent comprises Formula X:
  • n is 13 to 19, for example, n is 13, 14, 15, 16, 17, 18, 19 or 20.
  • the GLP-1 receptor agonist is a compound of Formula I or a pharmaceutically acceptable salt thereof, and the peptide of Formula I, or a pharmaceutically acceptable salt thereof, can be prepared by the method described in the Examples of CN101987868 , has the structure shown below:
  • the active ingredient GLP-1 receptor agonist of the present invention is contained in an amount of 0.5 to 15%, and may be 0.5, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, 5.0, 5.2, 5.4, 5.6, 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.6, 8.0, 8.4, 8.8, 9.0, 9.4, 9.6, 10.0, 10.6, 11.0, 13, 14, 15%, preferably from 1 to 5% by weight of the pharmaceutical composition.
  • the active ingredient is at most 10 mg by weight, and may be 0.5, 1, 2, 2.5, 3, 3.5, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8. , 8.5, 9, 9.5, 10 mg.
  • the NAC salt (N-(8-(2-hydroxybenzoyl)amino)octanoic acid) of the present invention may be crystalline and/or amorphous, and in embodiments, the delivery agent comprises any hydration of the NAC salt.
  • the delivery agent of the present invention is sodium NAC (referred to herein as "SNAC"), i.e., 8-(salicylamino)octanoate.
  • the salt of N-(8-(2-hydroxybenzoyl)amino)octanoic acid in the pharmaceutical composition of the present invention is used in an amount of 40 to 90% by weight based on the weight of the pharmaceutical composition, and may be 40, 42, or 44. 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90%, preferably 50 ⁇ 70%.
  • the amount of SNAC in the pharmaceutical composition of the invention is at most 400 mg, preferably at most 350 mg, and may be 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 130, 140, 150, 160, 165, 170, 180, 190, 200, 210, 220, 220, 230, 240 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350 mg.
  • the weight ratio of the active ingredient GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof and the NAC salt in the pharmaceutical composition is 1:10 or higher, that is, when measured by weight,
  • the NAC salt is 10 times or more the active ingredient, may be 1:30 or more, or 1:60 or more, preferably 1:30, which significantly increases the in vivo bioavailability of the pharmaceutical composition.
  • the pharmaceutical composition uses microcrystalline cellulose, which has a longer disintegration time and a lower dissolution rate, whereas lactose is used, and the pharmaceutical composition has a shorter disintegration time.
  • the amount of lactose is 10-40% by weight of the pharmaceutical composition, and may be 10, 11, 12, 13, 14 15, 15, 17, 18, 19, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40%, preferably 25 to 35%, by weight of the pharmaceutical composition.
  • water-soluble adjuvants similar in properties to lactose such as dextrin, sucrose, and mannitol, can also be used to achieve the above effects.
  • compositions of the present invention further comprise other pharmaceutical excipients known or determinable by those skilled in the art.
  • the pharmaceutical compositions of the present invention further comprise a disintegrating agent known or identifiable by those skilled in the art, selected from, but not limited to, sodium starch glycolate, methylol starch.
  • a disintegrating agent known or identifiable by those skilled in the art, selected from, but not limited to, sodium starch glycolate, methylol starch.
  • the pharmaceutical compositions of the present invention further comprise a lubricant, which may be selected from, but not limited to, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax, hard At least one of the sodium fumarate, preferably the lubricant is used in an amount of 0.1 to 5% by weight of the pharmaceutical composition, and the examples may be 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5%, based on the weight of the pharmaceutical composition.
  • a lubricant which may be selected from, but not limited to, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax, hard At least one of the sodium fumarate, preferably the lubricant is used in an amount of 0.1 to 5% by weight of the pharmaceutical composition, and the examples may be 0.1, 0.2
  • the pharmaceutical composition of the invention contains the following ingredients:
  • the disintegrant is selected from at least one of croscarmellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropylcellulose or crospovidone;
  • the lubricant is selected from the group consisting of hard At least one of magnesium stearate, stearic acid, palmitic acid, glyceryl behenate, calcium stearate, talc, carnauba wax, sodium stearyl fumarate; preferably, the active ingredient or
  • the weight ratio of the pharmaceutically acceptable salt to the delivery agent SNAC is 1:30.
  • the pharmaceutical composition of the present invention is prepared by pulverizing or pulverizing at least one of the active ingredient or a pharmaceutically acceptable salt thereof, SNAC and optionally at least one selected from the group consisting of a disintegrating agent, a filler, and a lubricant. Evenly, the uniformly mixed powder is granulated, and then granulated by granulator 2 to 3 times, and then added with additional lubricant, uniformly mixed, then compressed or filled into capsules, directly compressed or directly filled into capsules. .
  • the ratio of the amount of the lubricant added to the pharmaceutical composition of the present invention to the amount of the external lubricant is from 2:1 to 3:1 (weight ratio), and the pharmaceutical composition can be well avoided during the granulation process.
  • the buffering phenomenon ensures particle uniformity during granulation and ensures consistency of dissolution of the active ingredient in the pharmaceutical composition with the delivery agent SNAC.
  • the invention also provides a pharmaceutical composition comprising the following ingredients:
  • the amount of active ingredient can be 0.5, 2.5, 5, 10 mg; the amount of delivery agent SNAC can be 15, 25, 35, 45, 55, 65, 75, 85, 95, 150, 200, 250 300 mg, further, the weight ratio of the active ingredient to the delivery agent SNAC is 1:30.
  • the amount of lactose is at most 160 mg, and may be 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 75, 80, 160 mg;
  • the amount of sodium carboxymethylcellulose is at most 50 mg, preferably 20 mg, and may be 20 mg, 15 mg, 10 mg, 5 mg, 1 mg;
  • the amount of the lubricant magnesium stearate is at most 10.5 mg, which may be 1, 1.5. 2. 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5 mg.
  • the ratio of the amount of magnesium stearate to the amount of magnesium stearate added to the pharmaceutical composition of the present invention is from 2:1 to 3:1 (weight ratio), which can well avoid the granulation process.
  • the phenomenon of medium smashing ensures the uniformity of the granules during the granulation process and ensures the consistency of the active ingredient in the pharmaceutical composition with the delivery agent SNAC.
  • Factors affecting the disintegration time of the pharmaceutical composition are various, such as the influence of the tablet production process, the effect of the excipient and the main drug properties, and the storage conditions, etc., all of which can affect the disintegration time of the tablet to varying degrees, the present invention
  • the pharmaceutical composition was obtained by the same preparation process and parameters, and the disintegration time was determined under the same conditions.
  • the pharmaceutical composition of the present invention has a disintegration time of 2 to 10 minutes at a total weight of 125 mg to 250 mg, and may be 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5. 7, 7, 7.5, 8, 8.5, 9, 9.5, 10 minutes, preferably 4 to 8 minutes.
  • the pharmaceutical composition of the present invention may further comprise a coating agent, which may be, but not limited to, hypromellose, methyl cellulose, ethyl cellulose, methyl cellulose or hydroxy group.
  • a coating agent which may be, but not limited to, hypromellose, methyl cellulose, ethyl cellulose, methyl cellulose or hydroxy group.
  • a coating agent which may be, but not limited to, hypromellose, methyl cellulose, ethyl cellulose, methyl cellulose or hydroxy group.
  • a coating agent which may be, but not limited to, hypromellose, methyl cellulose, ethyl cellulose, methyl cellulose or hydroxy group.
  • the present invention also provides a method of preparing the above pharmaceutical composition, which comprises mixing an active ingredient or a pharmaceutically acceptable salt thereof with at least one selected from the group consisting of SNAC and a disintegrant, a filler, and a lubricant. 2)
  • the mixture obtained from 1) is granulated, tableted or filled, directly compressed or directly filled.
  • the "by weight of the pharmaceutical composition" of the present invention is a range of values of the amount of the active ingredient or other kind of excipient used to calculate the weight of the core without the coating agent. For details, see Example 1.
  • a coating step is further included, and the coating agent used is Opadry, hypromellose, ethyl cellulose or polyvinyl alcohol, preferably Opadry.
  • the granulation method used in the present invention may be wet granulation and dry granulation.
  • wet granulation scheme When the wet granulation scheme is selected, fluidized bed granulation or high shear wet granulation may be employed.
  • dry granulation process steps are as follows:
  • step 3 adding a lubricant to the granules in step 2 and mixing,
  • step 3 The mixture in step 3 is compressed into tablets.
  • the pharmaceutical composition of the present invention is a solid preparation, preferably a tablet, a granule, a powder (including fine granules), or a capsule.
  • the solid preparation can be obtained by a widely known preparation method, and the maximum water content of the final dried granule after granulation is controlled to be 3% or less, and then filled into capsules or directly packaged into granules.
  • the dosage form is a tablet
  • the humidity of the tableting environment is controlled during the tableting process to ensure that the water content of the final tablet is less than 3% (3% or less), and the final composition is ensured by vacuum drying the final composition.
  • the amount of water is less than 3%.
  • the pharmaceutical composition of the present invention employs a tablet
  • it can be prepared by compressing the granules obtained as described above.
  • the pressure of compression can be determined within an appropriate range.
  • the shape of the tablet is not particularly limited, and is preferably a lenticular shape, a disc shape, a circular shape, an elliptical shape (such as a caplet sheet), a teardrop shape or a polygonal shape (such as a triangle or a diamond shape).
  • the prepared tablets may be coated by spraying a suspension/solution of the coating agent through a pan coater. After the coating is completed, the moisture content of the final tablet is controlled to within 3% by a drying process.
  • the drying temperature can be selected from 40 to 80 °C.
  • the drying method can be carried out by ordinary oven drying or vacuum drying.
  • the granules obtained as described above may be used as they are or may be granulated into a desired granule by a suitable technique.
  • the granules thus prepared may be coated with a suspension of the spray coating agent with a coating agent.
  • the value of "related mass" of the present invention is obtained by HPLC detection.
  • HPLC detection conditions of the present invention are identical to HPLC detection conditions of the present invention:
  • the dissolution rate of the pharmaceutical composition of the present invention is determined according to the second method (paddle method) of the dissolution test of the Chinese Pharmacopoeia 2015 edition four-part general rule 0931, using 0.1% Tween 80 pH 6.8 phosphate buffer as the dissolution medium, preferably 500 ml. 0.1% Tween 80 pH 6.8 phosphate buffer, and the dissolution test of the composition of the invention at 37 ⁇ 0.5 ° C at a paddle speed of 50 rpm; in an embodiment, the pharmaceutical composition of the invention has a dissolution greater than 45 minutes. Equal to 90%, may be greater than or equal to 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%, with good dissolution rate and dissolution.
  • the pharmaceutical composition of the present invention has a dissolution degree of 80% or more in 15 minutes, and may be greater than or equal to 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90. 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%.
  • the pharmaceutical composition disintegration test of the present invention a disintegration test was carried out using a Tianda Tianfa Disintegration Tester. Set the time limit inspection method based on the Chinese Pharmacopoeia's four general rules 0921. The GL tablets were placed in a basket using a lift disintegrator, and the basket was immersed in 800 ml of purified water maintained at 37 ° C in a 1 L beaker. The time to complete disintegration was measured. In addition, the surface erosion behavior of the tablets was visually observed during the disintegration test.
  • the GLP-1 analog of the present invention provides a peptide of the formula I which belongs to the amphoteric compound.
  • the acid which is usually used to form the acid addition salt is: Hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid; salts including sulfates, Pyrosulfate, trifluoroacetate, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, hydrochloride, bromide, iodide, B Acid salt, propionate, octoate, acrylate,
  • Alkaline substances can also form salts with GLP-1 analogues, including ammonium, alkali metal or alkaline earth metal hydroxides, as well as carbonates, hydrogencarbonates, typically sodium hydroxide, potassium hydroxide. , ammonium hydroxide, sodium carbonate, potassium carbonate, etc.
  • the delivery agent of the present invention can be prepared, for example, by the methods described in WO 96/030036, WO 00/046182, WO 01/092206 or WO 2008/028859, or obtained commercially; the active ingredient of the present invention may be a peptide of the formula I or Pharmaceutically acceptable salts can be obtained by the methods described in CN101987868A.
  • the pharmaceutical excipients used in the present invention are commercially available, such as lactose and the like.
  • Figure 1 Dissolution profiles of Examples 1-3 in 0.1% Tween 80 pH 6.8 phosphate buffer;
  • Figure 2 Dissolution profiles of Examples 4-6 in 0.1% Tween 80 pH 6.8 phosphate buffer;
  • Figure 3 Dissolution profiles of Examples 5, 7-8 in 0.1% Tween 80 pH 6.8 phosphate buffer;
  • Figure 4 Dissolution profiles of Examples 8-10 in 0.1% Tween 80 pH 6.8 phosphate buffer.
  • the peptide represented by Formula I (hereinafter referred to as Compound A), SNAC, lactose or microcrystalline cellulose, croscarmellose sodium, povidone K30, and magnesium stearate were dry-processed according to the ratio in Table 1.
  • the granules are treated, then the dry granules are dry granulated, and a prescribed amount of magnesium stearate is added and mixed well. The resulting total mixed granules were compressed into tablets.
  • the filler is lactose, and the lactose is a water-soluble auxiliary material, during preparation.
  • the particles are relatively uniform and disintegrate faster; in the preparation process, the particle state is good in the preparation process, and the disintegration time is shortened after preparation into a tablet.
  • the dissolution rate of the tablets of Examples 1 to 3 was measured according to the second method (paddle method) of the dissolution test of the Chinese Pharmacopoeia 2015 edition of the general rules of the 0931 method. 500 ml of 0.1% Tween 80 pH 6.8 phosphate buffer was used as the dissolution medium, and the dissolution test was carried out at 37 ⁇ 0.5 ° C at a paddle speed of 50 rpm. The results showed that in Example 1, the dissolution of Compound A was incomplete and was inconsistent with the dissolution of SNAC. In Examples 2 to 3, the compound A was completely eluted and was consistent with the dissolution of SNAC. The dissolution data is shown in Table 2.
  • Compound A SNAC, lactose, croscarmellose sodium or crospovidone, low-substituted hydroxypropylcellulose, magnesium stearate are subjected to dry granulation according to the ratio in Table 3, and then The dry granules are dried and granulated, and a prescribed amount of magnesium stearate is added and mixed well. The resulting total mixed granules were compressed into tablets.
  • Example 4 croscarmellose sodium and crospovidone were used as disintegrants, and the tablet disintegrated faster; in Example 7, low-substituted hydroxypropylcellulose was used as a disintegrating agent. The disintegration time has increased.
  • the dissolution rate of the tablets of Examples 4 to 6 was measured according to the second method (paddle method) of the dissolution test of the Chinese Pharmacopoeia 2015 edition four general rules 0931. 500 ml of 0.1% Tween 80 pH 6.8 phosphate buffer was used as the dissolution medium, and the dissolution test was carried out at 37 ⁇ 0.5 ° C at a paddle speed of 50 rpm. The results showed that in Example 5, Compound A was completely eluted. In Examples 4 and 6, the dissolution rate of Compound A was slower than that in Example 5, and the final dissolution was not complete in Example 5. The dissolution data is shown in Table 4.
  • Compound A, SNAC, lactose, croscarmellose sodium, magnesium stearate were subjected to dry granulation treatment according to the ratio in Table 5, and then dry granules were dry granulated, and a prescribed amount of stearic acid was added. Magnesium, mixed evenly. The resulting total mixed granules were compressed into tablets.
  • the sample granule is easily adhered during the dry granulation process, which is disadvantageous for particle collection; in the embodiment 9, in the dry granulation process, the particles are uniform, there is no phenomenon of sticking the sample groove, and the particle has good fluidity, and the tablet is compressed. There is no overshoot in the process.
  • the dissolution rate of the tablets of Examples 8 to 9 was measured according to the second method (paddle method) of the dissolution test of the Chinese Pharmacopoeia 2015 edition four general rules 0931. 500 ml of 0.1% Tween 80 pH 6.8 phosphate buffer was used as the dissolution medium, and the dissolution test was carried out at 37 ⁇ 0.5 ° C at a paddle speed of 50 rpm. The results showed that in Examples 8-9, the particle uniformity was better at the time of granulation, the smear phenomenon was lighter, and the dissolution of Compound A and SNAC was better. The dissolution data is shown in Table 6.
  • Plasma treatment Collect whole blood into a centrifuge tube containing anticoagulant, store in an ice bath, centrifuge at 2 to 8 ° C, centrifuge at 3500 rpm / min, and centrifuge for 10 min. The collected plasma was divided into 2 portions and stored in an additionally labeled EP tube at -70 ⁇ 10 ° C until the sample was analyzed.
  • Blood samples were analyzed by bioanalytical researchers using LC-MS/MS methods to determine the concentrations of Compound A and SNAC in biological samples, and the bioanalytical data were analyzed by pharmacokinetics.
  • the bioavailability of the formulation of Example 1 relative to subcutaneous was 0.25%
  • the bioavailability of the formulation of Example 3 relative to subcutaneous was 0.36%
  • the bioavailability of the formulation of Example 9 relative to the subcutaneous was 0.68%.
  • Compound A, SNAC, lactose, croscarmellose sodium, magnesium stearate were subjected to dry granulation according to the ratio in Table 7, and then the dry granules were dry granulated, and a prescribed amount of stearic acid was added. Magnesium, mixed evenly. The resulting total mixed granules were compressed into tablets.
  • the dissolution rate of the tablets of Examples 10 to 11 was measured according to the second method (paddle method) of the dissolution test of the Chinese Pharmacopoeia 2015 edition four general rules 0931. 500 ml of 0.1% Tween 80 pH 6.8 phosphate buffer was used as the dissolution medium, and the dissolution test was carried out at 37 ⁇ 0.5 ° C at a paddle speed of 50 rpm. The results showed that in Examples 10 to 11, Compound A was completely eluted and was consistent with the dissolution of SNAC. The dissolution data is shown in Table 8.
  • Example 9 and Example 10 were allowed to stand under accelerated conditions (40 ° C, RH 75%) for 3 months, and the product quality was stable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique d'un analogue du glucagon-like peptide-1 (GLP-1) et son procédé de préparation. Spécifiquement, la présente invention concerne une composition pharmaceutique contenant un agoniste du récepteur de GLP-1 et un sel d'acide (NAC) de N-(8-(2-hydroxyphénylméthyl)amino)octanoïque, la composition pharmaceutique ayant un temps de désintégration relativement court et un excellent taux de dissolution.
PCT/CN2017/119613 2016-12-30 2017-12-29 Composition pharmaceutique d'analogue du glp-1 et son procédé de préparation Ceased WO2018121702A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780020541.2A CN108883073B (zh) 2016-12-30 2017-12-29 一种glp-1类似物的药物组合物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611253129.9 2016-12-30
CN201611253129 2016-12-30

Publications (1)

Publication Number Publication Date
WO2018121702A1 true WO2018121702A1 (fr) 2018-07-05

Family

ID=62707881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/119613 Ceased WO2018121702A1 (fr) 2016-12-30 2017-12-29 Composition pharmaceutique d'analogue du glp-1 et son procédé de préparation

Country Status (3)

Country Link
CN (1) CN108883073B (fr)
TW (1) TW201822787A (fr)
WO (1) WO2018121702A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117241821A (zh) * 2022-03-25 2023-12-15 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法
WO2024017139A1 (fr) * 2022-07-20 2024-01-25 成都海博为药业有限公司 Composition pharmaceutique contenant un analogue agoniste du récepteur glp-1
CN118319871A (zh) * 2024-04-19 2024-07-12 鲁南新时代生物技术有限公司 一种司美格鲁肽药物组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111265654B (zh) * 2018-12-05 2023-05-16 江苏恒瑞医药股份有限公司 Glp-1类似物的药物组合物及其制备方法
CN111617257A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种阿比特龙或其衍生物药物组合物及其应用
EP4025353B1 (fr) 2019-09-06 2024-11-06 Novo Nordisk A/S Procédé et équipement de fractionnement de granules à utiliser dans des compositions pharmaceutiques
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012080A1 (fr) * 2009-07-30 2011-02-03 江苏豪森医药集团有限公司 Dérivé de l'analogue du glp-1 ou ses sels pharmaceutiques et leur utilisation
WO2013037985A1 (fr) * 2011-09-16 2013-03-21 Genmedica Theraputics Sl Combinaisons pharmaceutiques contenant des conjugués anti-inflammatoire- antioxydant et destinées à être utilisées en vue du traitement d'affections métaboliques
WO2013139695A1 (fr) * 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprenant un agent de transport et préparation de celles-ci
WO2013189988A1 (fr) * 2012-06-20 2013-12-27 Novo Nordisk A/S Formulation de comprimés comprenant un peptide et un agent d'administration
CN105753764A (zh) * 2016-01-13 2016-07-13 贵州医科大学 二氢吲哚-3-羧酸衍生物及其在药物中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012080A1 (fr) * 2009-07-30 2011-02-03 江苏豪森医药集团有限公司 Dérivé de l'analogue du glp-1 ou ses sels pharmaceutiques et leur utilisation
WO2013037985A1 (fr) * 2011-09-16 2013-03-21 Genmedica Theraputics Sl Combinaisons pharmaceutiques contenant des conjugués anti-inflammatoire- antioxydant et destinées à être utilisées en vue du traitement d'affections métaboliques
WO2013139695A1 (fr) * 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprenant un agent de transport et préparation de celles-ci
WO2013189988A1 (fr) * 2012-06-20 2013-12-27 Novo Nordisk A/S Formulation de comprimés comprenant un peptide et un agent d'administration
CN105753764A (zh) * 2016-01-13 2016-07-13 贵州医科大学 二氢吲哚-3-羧酸衍生物及其在药物中的应用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117241821A (zh) * 2022-03-25 2023-12-15 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法
CN117241821B (zh) * 2022-03-25 2024-04-09 北京质肽生物医药科技有限公司 多肽缀合物的药物组合物及其使用方法
WO2024017139A1 (fr) * 2022-07-20 2024-01-25 成都海博为药业有限公司 Composition pharmaceutique contenant un analogue agoniste du récepteur glp-1
CN118319871A (zh) * 2024-04-19 2024-07-12 鲁南新时代生物技术有限公司 一种司美格鲁肽药物组合物

Also Published As

Publication number Publication date
CN108883073A (zh) 2018-11-23
TW201822787A (zh) 2018-07-01
CN108883073B (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
WO2018121702A1 (fr) Composition pharmaceutique d'analogue du glp-1 et son procédé de préparation
TWI804571B (zh) 包含glp-1促效劑及n-(8-(2-羥苯甲醯基)胺基)辛酸之鹽的固體組成物
KR101925620B1 (ko) Ｇｌｐ-1 아고니스트 및 ｎ-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
JP4969586B2 (ja) マルチプルユニット型徐放性経口製剤およびその製造方法
KR101406767B1 (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도
ES2642788T3 (es) Fabricación de gránulos sin principio activo y de comprimidos que comprenden los mismos
CN101267810A (zh) 吡非尼酮与药物可接受的赋型剂的胶囊制剂
JP2016531912A (ja) 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物
JP2011140498A (ja) フェソテロジンを含む安定した医薬組成物
TW201100127A (en) Solid pharmaceutical compositions and processes for their production
TW201038300A (en) Galenic formulations of organic compounds
JP7231255B2 (ja) 改善されたブロモクリプチン製剤
US20220409701A1 (en) Process for producing a tablet comprising glp-1 peptides
JP2022543826A (ja) Ｐｙｙ化合物とｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
WO2021238978A1 (fr) Composition pharmaceutique contenant un promédicament de nitroxoline, méthode de préparation et application de celle-ci
CN111265654B (zh) Glp-1类似物的药物组合物及其制备方法
JP6680297B2 (ja) 経口投与用医薬組成物
WO2017028660A1 (fr) Composition pharmaceutique contenant un dérivé de la quinoléine ou un sel correspondant
WO2007016679A2 (fr) Formes posologiques combinees a base de levodopa et de carbidopa a liberation immediate et a liberation controlee
BRPI1007237B1 (pt) Composição farmacêutica compreendendo aleglitazar
CN114533690A (zh) 含抗凝血药物西洛他唑的新制剂及其制备方法
TW201904572A (zh) 非布司他控釋組合物及其製備方法
JP2016510787A (ja) クリゾチニブを含む剤形
CN105796503A (zh) 一种沙格列汀微丸及其制剂
KR102271862B1 (ko) 리바록사반 함유 경구용 고형제제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17888880

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17888880

Country of ref document: EP

Kind code of ref document: A1